Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.
Divided into supraventricular and ventricular tachycardia.
Signs and symptoms related to rapid heart rate are altered sensorium,
angina, shortness of breath, myocardial infarction, hypotension and
other signs of shock (eg cold clammy skin, low urine output), heart
failure or pulmonary congestion.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
The use of a wearable cardioverter-defibrillator (WCD) may be a suitable alternative for paediatric patients with life-threatening ventricular arrhythmias who are not candidates for implantable cardioverter-defibrillators (ICDs), a recent study showed.
Use of implantable cardioverter defibrillator (ICD) for primary prevention significantly reduces all-cause mortality compared with conventional care for patients who had heart failure with reduced ejection fraction (HFrEF), according to a meta-analysis.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.